Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Systemic lupus erythematosus

전신성 홍반성 루푸스

  • Kim, Kwang-Nam (Department of Pediatrics, College of Medicine, Hallym University)
  • 김광남 (한림대학교 의과대학 소아과학교실)
  • Received : 2007.10.20
  • Accepted : 2007.11.25
  • Published : 2007.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

Systemic lupus erythematosus (SLE) is an episodic, multi-system, autoimmune disease characterized by widespread inflammation of blood vessels and connective tissues and by the presence of antinuclear antibodies (ANAs), especially antibodies to native (double-stranded) DNA (dsDNA). Its clinical manifestations are extremely variable, and its natural history is unpredictable. Untreated, SLE is often progressive and has a significant fatality rate. The most widely used criteria for the classification of SLE are those of the American College of Rheumatology (ACR), which were revised in 1982 and modified in 1997. The presence of four criteria have been diagnosed as a SLE. Rashes are common at onset and during active disease. The oral mucosa is the site of ulceration with SLE. Arthralgia and arthritis affect most children and these symptoms are short in duration and can be migratory. Lupus nephritis may be more frequent and of greater severity in children than in adults. The initial manifestation of nephritis is microscopic hematuria, followed by proteinuria. The most common neuropsychiatric symptoms are depression, psychosis(hallucination and paranoia) and headache. CNS disease is a major cause of morbidity and mortality. Pericarditis is the most common cardiac manifestation. Libman-Sacks endocarditis is less common in children. The most frequently described pleuropulmonary manifestations are pleural effusions, pleuritis, pneunonitis and pulmonary hemorrhage. During the active phase ESR, CRP, gamma globulin, ferritin and anti-dsDNA are elevated. Antibodies to dsDNA occur in children with active nephritis. Antibodies to the extractable nuclear antigens (Sm, Ro/SS-A, La/SS-B) are strongly associated with SLE. Specific treatment should be individualized and based on the severity of the disease. Sepsis has replaced renal failure as the most common cause of death.

Keywords

References

  1. Smith CD, Cyr M. The history of lupus erythematosus from Hippocrates to Osler. Rheum Dis Clin North Am 1988;14:1-14
  2. Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med 1895;110:629-46 https://doi.org/10.1097/00000441-189512000-00001
  3. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924;33:701- 37 https://doi.org/10.1001/archinte.1924.00110300044002
  4. Baehr G, Kemperer P, Schifrin A. A diffuse disease of the peripheral circulation usually associated with lupus erythematsus and endocraditis. Trans Assoc Am Phys 1935; 50:139
  5. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the Tart cell and the L.E. cell. Mayo Clin Proc 1948;23:25-8
  6. Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of Pediatrics Rheumatology. IN: Petty RE. Laxer RM, editors. Systemic Lupus Erythematosus. 5th ed. Philadelphia: Elsevier Saunders Ins, 2005:342-91
  7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7 https://doi.org/10.1002/art.1780251101
  8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
  9. Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: result from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996;23:1981-7
  10. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-8 https://doi.org/10.1002/art.1780380415
  11. Klippel JH. Rheumatology. 3rd ed. London: Mosby Co, 2004:1292
  12. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431-56 https://doi.org/10.1146/annurev.immunol.22.012703.104549
  13. Clinic Rheumatology editors. Clinic Rheumatology IN: Systemic lupus erythematosus. 1st ed. Seoul: Korea Medicine Co, 2006:353-406
  14. Athreya BH, Rafferty JH, Sehgal GS, Lahita RG. Adenohypophyseal and sex hormones in pediatric rheumatic diseases. J Rheumatol 1993;20:725-30
  15. Miranda-Carus ME, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-30 https://doi.org/10.1084/jem.179.4.1317
  16. Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 1998;16:289-94
  17. Wananukul S, Watana D, Pongprasit P. Cutaneous manifestations of childhood systemic lupus erythematosus. Pediatr Dermatol 1998;15:342-6 https://doi.org/10.1046/j.1525-1470.1998.1998015342.x
  18. Smith FE, Sweet DE, Brunner CM, Davis JS. Avascular necrosis in SLE: an apparent predilection for young patients. Ann Rheum Dis 1976;35:227-32 https://doi.org/10.1136/ard.35.3.227
  19. Cameron JS. Lupus nephritis in childhood and adolescene. Pediatr Nephrol 1994;8:230-49 https://doi.org/10.1007/BF00865490
  20. Silber TJ, Chatoor I, White PH. Psychiatric manifestations of systemic lupus erythematosus in children and adolescents. Clin Pediatr 1984;23:331-5 https://doi.org/10.1177/000992288402300606
  21. Ilowite NT, Samuel P, Ginzler E. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-63 https://doi.org/10.1002/art.1780310706
  22. De Jongste JC, Neijens HJ, Duiverman EJ. Respiratory tract disease in systemic lupus erythematosus. Arch Dis Child 1986;61:478-83 https://doi.org/10.1136/adc.61.5.478
  23. Kokk A, Horneff G, Wilgenbus KK. Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus. Possible toxicity of immunosuppressive therapy. Clin Exp Rheumatol 1995;13:399-403
  24. Gibson T, Myers AR. Subclinical liver disease in systemic lupus erythemato년. J Rheumatol 1981;8:752-9
  25. Au A, O'Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: association, visual outcomes, complications and treatment. Clin Exp Opthalmol 2004;32:87-100 https://doi.org/10.1046/j.1442-9071.2004.00766.x
  26. Ansari A, Larson PH, Bates HD. Vascular manifestations of systemic lupus erythematosus. Angiology 1986;37:423-32 https://doi.org/10.1177/000331978603700601
  27. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996;39: 1050-5 https://doi.org/10.1002/art.1780390625
  28. Bowyer SL, Ragsdale CG, Sullivan DB. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol 1989;16:1093-97.
  29. Lehman TJ, Hanson V, Singsen BH. The role of antibodies directed against double-stranded DNA in the manifestations of systemic lupus erythematosus in childhood. J Pediatr 1980;96:657-61 https://doi.org/10.1016/S0022-3476(80)80733-5
  30. Reichlin M. Antibodies to ribonuclear proteins in systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20: 29-43
  31. Taylor PV, Scott JS, Gerlis LM. Maternal autoantibodies against fetal cardiac antigens in congenital complete heart block. N Engl J Med 1986;315:667-72 https://doi.org/10.1056/NEJM198609113151103
  32. Beaufils M, Kouki F, Mignon F. Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med 1983;74:201-5 https://doi.org/10.1016/0002-9343(83)90612-5
  33. Sharp GC, Irvin WS, Tan EM. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972;52:148-59 https://doi.org/10.1016/0002-9343(72)90064-2
  34. Fritzler MJ, Tan EM. Antibodies to histone in druginduced and idiopathic lupus erythematosus. J Clin Invest 1978;62:560-7 https://doi.org/10.1172/JCI109161
  35. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424-32 https://doi.org/10.1136/jcp.53.6.424
  36. Mandell BF, Raps ED. Severe systemic hypersensitivity reaction of ibuprofen occurring after prolonged therapy. Am J Med 1987;82:817-20 https://doi.org/10.1016/0002-9343(87)90021-0
  37. Wallace DJ, Metzger AL, Stecher VJ. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6 https://doi.org/10.1016/0002-9343(90)90345-E
  38. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2002;10:140-7 https://doi.org/10.1191/096120301675075008
  39. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984;311:1528-33 https://doi.org/10.1056/NEJM198412133112402
  40. Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematsus. Lupus 2001;10: 152-3 https://doi.org/10.1191/096120301676669495
  41. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatments of systemic lupus erythematosus. Lupus 2001;10:154-61 https://doi.org/10.1191/096120301671376017
  42. Valesini G, Priori R, Francia A. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semi Immunopatho 1994;16:313-21
  43. Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004;63:321-23 https://doi.org/10.1136/ard.2003.008342
  44. Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin A(Neoral) in the treatment of paediatric lupus nephritis with heavy protenuria. Br J Rheumatol 1998;37: 217-21 https://doi.org/10.1093/rheumatology/37.2.217
  45. Ginzler EM, Aranow C, Buyon J. A multicenter study of mycophenolate mofetil(MMF) vs intravenous cyclophosphamide( IVC) as induction therapy for severe lupus nephritis: preliminary results. Arthritis Rheum 2003;48:s647
  46. Lafferty TE, Smith JB, Schuster SJ, DeHortius RJ. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Rrthritis Rheum 1997;40:775-8 https://doi.org/10.1002/art.1780400426
  47. Wang LC, Yang YH, Lu MY. Retrospective analysis of mortality and morbidity of pediatric SLE in the past two decades. J Mirobiol Immunol Infect 2003;36:203-8